CATIE Cost-Effectiveness Study Favors Perphenazine Over Atypicals
Executive Summary
The first-generation antipsychotic perphenazine (Schering-Plough's Trilafon and generics) is less costly and just as effective in treating schizophrenia as second-generation antipsychotics, according to an economic analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) program
You may also be interested in...
CER Credibility Lies In Methodology For Studies, Physician Tells BIO
The credibility of comparative effectiveness research ultimately will be judged based on the methodology used to conduct the research, David Charles, associate professor and vice-chairman of neurology at Vanderbilt University Medical Center and chairman of the physician group Alliance for Patient Access, told attendees during a session at the Biotechnology Industry Organization International Convention.
CER Credibility Lies In Methodology For Studies, Physician Tells BIO
The credibility of comparative effectiveness research ultimately will be judged based on the methodology used to conduct the research, David Charles, associate professor and vice-chairman of neurology at Vanderbilt University Medical Center and chairman of the physician group Alliance for Patient Access, told attendees during a session at the Biotechnology Industry Organization International Convention.
Antipsychotic Drugs Are Medco's New Personalized Medicine Target
Medco will launch a research project in November that aims to validate a biomarker that may improve the cost effectiveness of atypical antipsychotics. The pharmacy benefit manager announced a research collaboration with development-stage genetic test developer SureGene on Aug. 24